OSE Immunotherapeutics S.A.
ORPOF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$104.85M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $104.85 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $- |
| Beta | 0.85 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.26 |
|---|---|
| PEG | -8.7 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
October 22, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About OSE Immunotherapeutics S.A.
64 employees
CEO: Marc Le Bozec
Headquartered in Nantes, France, OSE Immunotherapeutics S.A. is a biotechnology company dedicated to pioneering immunotherapies. Its research and development efforts are concentrated on modulating immune responses, specifically in the do...